

Ida Paris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5958530/publications.pdf>

Version: 2024-02-01

35
papers

676
citations

566801

15
h-index

580395

25
g-index

35
all docs

35
docs citations

35
times ranked

1189
citing authors

#	ARTICLE	IF	CITATIONS
1	Level II Oncoplastic Surgery as an Alternative Option to Mastectomy with Immediate Breast Reconstruction in the Neoadjuvant Setting: A Multidisciplinary Single Center Experience. <i>Cancers</i> , 2022, 14, 1275.	1.7	6
2	PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. <i>Cancers</i> , 2022, 14, 2161.	1.7	15
3	Pregnancy-Associated Breast Cancer: A Multidisciplinary Approach. <i>Clinical Breast Cancer</i> , 2021, 21, e120-e127.	1.1	17
4	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	1.7	35
5	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	1.1	5
6	Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes. <i>Journal of Personalized Medicine</i> , 2021, 11, 324.	1.1	9
7	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	1.3	41
8	Techniques for sentinel node biopsy in breast cancer. <i>Minerva Surgery</i> , 2021, 76, .	0.1	3
9	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	1.7	12
10	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021, 13, 5198.	1.7	10
11	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
12	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
13	Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2+ Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. <i>Journal of Personalized Medicine</i> , 2020, 10, 291.	1.1	4
14	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
15	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	3.0	59
16	Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome. <i>Cancers</i> , 2020, 12, 1286.	1.7	21
17	A multicenter Retrospective observational study of first-line treatment with Pertuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	1.5	30
18	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Novel BRCA1 Large Genomic Rearrangements in Italian Breast/Ovarian Cancer Patients. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 121-126.	1.6	7
20	Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Hyperthermia</i> , 2018, 35, 370-374.	1.1	28
21	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 41, 137-143.	0.9	41
22	Axillary lymph node surgical treatment. <i>Translational Cancer Research</i> , 2018, 7, S390-S404.	0.4	2
23	Management of BRCA mutation carriers. <i>Translational Cancer Research</i> , 2018, 7, S329-S338.	0.4	0
24	Current controversies in the treatment of ductal carcinoma in situ of the breast. <i>Translational Cancer Research</i> , 2018, 7, S307-S318.	0.4	1
25	Characterization of a new BRCA1 rearrangement in an Italian woman with hereditary breast and ovarian cancer syndrome. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 497-503.	1.1	16
26	BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 334.e1-334.e9.	0.7	65
27	Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals. <i>Breast</i> , 2017, 36, 74-78.	0.9	9
28	Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1141-1148.	1.2	3
29	Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 157-164.	0.8	12
30	Efficacy and safety of T-DM1 in the "common-practice"™ of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017, 8, 64481-64489.	0.8	22
31	Widespread Renal Polycystosis Induced by Crizotinib. <i>Tumori</i> , 2015, 101, e128-e131.	0.6	5
32	Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 952-958.	0.7	51
33	Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. <i>Anticancer Research</i> , 2014, 34, 5241-50.	0.5	14
34	A Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of 5-Fluorouracil Degradation Rate by Intact Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 482-488.	1.0	31
35	Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. <i>Gynecologic Oncology</i> , 2005, 98, 267-273.	0.6	39